Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial

Fineline Cube Dec 22, 2025
Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Fineline Cube Dec 22, 2025
Company Deals

CanSinoBIO Licenses ISL‑3C‑LNP Platform to PanRu Biotech – $100 M+ Deal to Accelerate mRNA Cancer Vaccines

Fineline Cube Nov 11, 2025

CanSino Biologics Inc. (HKG: 6185) announced today a licensing agreement with PanRu Biotechnology (Tianjin) Co.,...

Company Deals

Eisai China and Beckman Coulter Launch Alzheimer’s Blood‑Test Collaboration in Mainland China

Fineline Cube Nov 10, 2025

Eisai China Holdings (TYO: 4523) and Beckman Coulter Laboratory Systems (Suzhou) Co., Ltd. today signed...

Company Drug

Gilead Sciences’ Tro Delvy Fails to Meet Primary Endpoint in ASCENT‑07 Metastatic Breast Cancer Trial

Fineline Cube Nov 10, 2025

Gilead Sciences Inc. (NASDAQ: GILD) today disclosed that the Phase III ASCENT‑07 study, which compared Trodelvy...

Company Deals

Insilico Medicine & Eli Lilly Forge Strategic AI‑Driven Drug Discovery Alliance

Fineline Cube Nov 10, 2025

Insilico Medicine, a leader in artificial‑intelligence‑powered drug discovery, today announced a strategic collaboration with Eli Lilly (NYSE:...

Company Deals

SanegeneBio & Eli Lilly Sign Global Partnership to Advance RNAi Therapies for Metabolic Diseases

Fineline Cube Nov 10, 2025

SanegeneBio, a biotechnology company specializing in RNAi therapeutics, today announced a global research collaboration and...

Company Deals

DeliNova Raises Nearly RMB 60 Million in Seed & Angel Financing for In‑Vivo CAR‑T Platform

Fineline Cube Nov 10, 2025

Nantong DeliNova Therapeutics Co., Ltd. announced today the successful closing of a seed‑stage financing round...

Company Deals

Organon Acquires JADA System from Laborie for USD 465 Million

Fineline Cube Nov 10, 2025

Organon Inc. (NYSE: OGN) announced today that it has entered into an agreement with Laborie...

Company Deals Digital

HBM Holdings and Evinova Form AI‑Powered Biologic Therapy Collaboration

Fineline Cube Nov 10, 2025

HBM Holdings Limited (HKG: 2142) and Evinova, an independent health‑tech arm of the AstraZeneca Group,...

Company Drug

Jiangsu Hengrui Pharmaceuticals Announces HRS‑2430 Injection Approval for Clinical Trials

Fineline Cube Nov 10, 2025

China‑listed Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that its novel intravenous...

Others

National Health Commission’s Negative Behavior List for Medical Staff Internet‑Based Health Science Popularization (Trial)

Fineline Cube Nov 10, 2025

The National Health Commission (NHC) announced on 7 November 2025 a “Negative Behavior List for Medical Staff...

Company Deals

Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal

Fineline Cube Nov 10, 2025

Novo Nordisk A/S (NYSE: NVO) confirmed today that it will not pursue an increased offer...

Company Deals

Aureka Biotechnologies Closes Multi‑Million‑Dollar Series A – Generative Antibody Platform Gains 5Y Capital & Qiming Backing

Fineline Cube Nov 10, 2025

Aureka Biotechnologies, a pioneer in generative antibody drug development, announced today the successful close of...

Company Deals

Zhaoke Ophthalmology Indonesia Distribution Deal – BRIMOCHOL PF Eyes on Market Expansion

Fineline Cube Nov 8, 2025

China‑listed Zhaoke Ophthalmology Ltd. (HKG: 6622) announced a new distribution and supply agreement with Indonesia’s...

Company Deals

Shanghai‑Boehringer Ingelheim MOU Launches Stroke Prevention Initiative – Strengthening China Health 2030

Fineline Cube Nov 8, 2025

During the 8th China International Import Expo (CIIE), the Shanghai Medical Association (SMA) and Boehringer Ingelheim...

Company Deals Hospital

Boehringer Ingelheim Taps Beijing Friendship Hospital for MASH Trials – Expands China Key Initiative

Fineline Cube Nov 8, 2025

Boehringer Ingelheim announced at the 8th China International Import Expo (CIIE) that it has signed...

Company

Zai Lab Q3 2025 Revenue Up 13% YoY to $115.4 M, Led by Nuzyra and Xacduo; Zejula Slows

Fineline Cube Nov 8, 2025

Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) released its third‑quarter 2025 financial results, reporting total...

Company Deals

Eisai China Partners with Shanghai Pharmaceuticals Holding – Focus on Oncology, Neuroscience and Sleep Disorders

Fineline Cube Nov 8, 2025

In a high‑profile signing at the 8th China International Import Expo (CIIE), Eisai China (TYO:...

Policy / Regulatory

NHSA Pilot AI Review Accelerates Full‑Process Medical Insurance Assessment in 7 Chinese Provinces

Fineline Cube Nov 8, 2025

The National Healthcare Security Administration (NHSA) has announced a three‑phase, AI‑powered review pilot covering Beijing,...

Policy / Regulatory

US FDA’s CNPV Fast‑Track Program Expands to 15 Drugs, Cutting Review Time to Months

Fineline Cube Nov 8, 2025

The Commissioner’s National Priority Voucher (CNPV) pilot has just added 15 therapies to its two‑batch...

Company Deals

Sichuan Biokin Launches on HKEX, Raises HK$3.3 B in $389/Share Offering – A Milestone for China’s Biotech

Fineline Cube Nov 8, 2025

China’s Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced its successful initial public offering (IPO)...

Posts pagination

1 … 16 17 18 … 600

Recent updates

  • Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial
  • Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis
  • MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED
  • Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal
  • Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial

Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.